mgn-1703 Search Results


mgn1703  (MOLOGEN Inc)
90
MOLOGEN Inc mgn1703
Recruitment of participants and outline of study design. A, Flow diagram depicting the recruiting of human immunodeficiency virus–infected participants for <t>MGN1703</t> treatment. B, Outline of study design. Participants received a total of 8 doses of MGN1703 during 4 weeks (down arrows). Blood samples (up arrows) for plasma cytokines and flow cytometry were drawn at the screening visit, baseline, during the first week (day 4 or 5, “early”) and last (day 25, “late”) week of MGN1703 treatment and at follow-up (day 37).
Mgn1703, supplied by MOLOGEN Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgn-1703/mgn1703/pmc05849129-140-34-35
Average 90 stars, based on 1 article reviews
mgn1703 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Recruitment of participants and outline of study design. A, Flow diagram depicting the recruiting of human immunodeficiency virus–infected participants for MGN1703 treatment. B, Outline of study design. Participants received a total of 8 doses of MGN1703 during 4 weeks (down arrows). Blood samples (up arrows) for plasma cytokines and flow cytometry were drawn at the screening visit, baseline, during the first week (day 4 or 5, “early”) and last (day 25, “late”) week of MGN1703 treatment and at follow-up (day 37).

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

doi: 10.1093/cid/cix201

Figure Lengend Snippet: Recruitment of participants and outline of study design. A, Flow diagram depicting the recruiting of human immunodeficiency virus–infected participants for MGN1703 treatment. B, Outline of study design. Participants received a total of 8 doses of MGN1703 during 4 weeks (down arrows). Blood samples (up arrows) for plasma cytokines and flow cytometry were drawn at the screening visit, baseline, during the first week (day 4 or 5, “early”) and last (day 25, “late”) week of MGN1703 treatment and at follow-up (day 37).

Article Snippet: As 120 mg MGN1703 per week is considered safe in cancer patients and healthy controls [ 18 , 21 , 22 ], study participants received 4 weeks of 60 mg (concentration 15 mg/mL) of MGN1703 (MOLOGEN AG, Berlin, Germany), administered subcutaneously by the study investigator as two 2-mL bilateral injections twice weekly.

Techniques: Virus, Infection, Clinical Proteomics, Flow Cytometry

Adverse Events and Their Severity During MGN1703 Treatment (N = 15)

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

doi: 10.1093/cid/cix201

Figure Lengend Snippet: Adverse Events and Their Severity During MGN1703 Treatment (N = 15)

Article Snippet: As 120 mg MGN1703 per week is considered safe in cancer patients and healthy controls [ 18 , 21 , 22 ], study participants received 4 weeks of 60 mg (concentration 15 mg/mL) of MGN1703 (MOLOGEN AG, Berlin, Germany), administered subcutaneously by the study investigator as two 2-mL bilateral injections twice weekly.

Techniques: Injection, Infection

MGN1703 increased expression of CD86 and CD40 on plasmacytoid dendritic cells. Flow cytometry analyses of fresh peripheral blood mononuclear cells were performed at the indicated time-points: baseline, day 0; early, day 5 (48 hours after second dose); late, day 24 (24 hours after eighth/last dose); and follow-up, 14 days after the last dose (n = 15). A, Plasmacytoid dendritic cell (pDC) expression levels of the marker CD86 (median fluorescence intensity [MFI]). B, pDC expression levels of the marker CD40 (MFI). C, Proportions of pDCs of total mononuclear cells. Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05; **P < .01; ***P < .001.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

doi: 10.1093/cid/cix201

Figure Lengend Snippet: MGN1703 increased expression of CD86 and CD40 on plasmacytoid dendritic cells. Flow cytometry analyses of fresh peripheral blood mononuclear cells were performed at the indicated time-points: baseline, day 0; early, day 5 (48 hours after second dose); late, day 24 (24 hours after eighth/last dose); and follow-up, 14 days after the last dose (n = 15). A, Plasmacytoid dendritic cell (pDC) expression levels of the marker CD86 (median fluorescence intensity [MFI]). B, pDC expression levels of the marker CD40 (MFI). C, Proportions of pDCs of total mononuclear cells. Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05; **P < .01; ***P < .001.

Article Snippet: As 120 mg MGN1703 per week is considered safe in cancer patients and healthy controls [ 18 , 21 , 22 ], study participants received 4 weeks of 60 mg (concentration 15 mg/mL) of MGN1703 (MOLOGEN AG, Berlin, Germany), administered subcutaneously by the study investigator as two 2-mL bilateral injections twice weekly.

Techniques: Expressing, Flow Cytometry, Marker, Fluorescence

MGN1703 treatment activates memory subsets of CD4+ and CD8+ T cells. Flow cytometry analyses of fresh peripheral blood mononuclear cells were performed at the indicated time-points: baseline, day 0; late, day 24 (24 hours after eighth/last dose). A, HLA-DR+ and CD38+ coexpression analyses on CD4+ T-cell subsets: naive (TN), central memory (TCM), effector memory (TEM), and terminal differentiated (TTD). B, Proportions of the 4 CD4+ T-cell subsets of total CD4+ T cells. C, HLA-DR+ and CD38+ coexpression analyses on CD8+ T-cell subsets: TN, TCM, TEM, TTD. D, Proportions of the 4 CD8+ T-cell subsets of total CD8+ T cells (n = 11). Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05; **P < .01; ***P < .001.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

doi: 10.1093/cid/cix201

Figure Lengend Snippet: MGN1703 treatment activates memory subsets of CD4+ and CD8+ T cells. Flow cytometry analyses of fresh peripheral blood mononuclear cells were performed at the indicated time-points: baseline, day 0; late, day 24 (24 hours after eighth/last dose). A, HLA-DR+ and CD38+ coexpression analyses on CD4+ T-cell subsets: naive (TN), central memory (TCM), effector memory (TEM), and terminal differentiated (TTD). B, Proportions of the 4 CD4+ T-cell subsets of total CD4+ T cells. C, HLA-DR+ and CD38+ coexpression analyses on CD8+ T-cell subsets: TN, TCM, TEM, TTD. D, Proportions of the 4 CD8+ T-cell subsets of total CD8+ T cells (n = 11). Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05; **P < .01; ***P < .001.

Article Snippet: As 120 mg MGN1703 per week is considered safe in cancer patients and healthy controls [ 18 , 21 , 22 ], study participants received 4 weeks of 60 mg (concentration 15 mg/mL) of MGN1703 (MOLOGEN AG, Berlin, Germany), administered subcutaneously by the study investigator as two 2-mL bilateral injections twice weekly.

Techniques: Flow Cytometry

MGN1703 treatment induce detectable plasma viremia. A, Analyses of plasma human immunodeficiency virus type 1 (HIV-1) RNA revealed that 6 of 15 participants had quantifiable plasma HIV-1 RNA (range, 21–1571 copies/mL) during MGN1703 treatment. Gray area represents the 4-week dosing period. B, Cell-associated unspliced (CA-US) HIV-1 RNA from 1 × 106 CD4+ T cells. Time-points depicted in the graph are as follows: “baseline”: average of day –30 and day 0 data (prior to dosing); day 4 (24 hours after second dose); day 5 (48 hours after second dose); day 10 (48 hours after third dose); day 24 (24 hours after eighth/last dose); follow-up: average of follow-up visit data on day 37 and 79 (14 and 42 days after last dose). No measurable induction of HIV-1 transcription was observed in peripheral blood during MGN1703 treatment; however, a significant reduction was observed at follow-up (n = 13). C, Total HIV-1 DNA (n = 14) was analyzed with digital droplet polymerase chain reaction from 5 × 106 CD4+ T cells on baseline and follow-up (14 days after last dose). Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

doi: 10.1093/cid/cix201

Figure Lengend Snippet: MGN1703 treatment induce detectable plasma viremia. A, Analyses of plasma human immunodeficiency virus type 1 (HIV-1) RNA revealed that 6 of 15 participants had quantifiable plasma HIV-1 RNA (range, 21–1571 copies/mL) during MGN1703 treatment. Gray area represents the 4-week dosing period. B, Cell-associated unspliced (CA-US) HIV-1 RNA from 1 × 106 CD4+ T cells. Time-points depicted in the graph are as follows: “baseline”: average of day –30 and day 0 data (prior to dosing); day 4 (24 hours after second dose); day 5 (48 hours after second dose); day 10 (48 hours after third dose); day 24 (24 hours after eighth/last dose); follow-up: average of follow-up visit data on day 37 and 79 (14 and 42 days after last dose). No measurable induction of HIV-1 transcription was observed in peripheral blood during MGN1703 treatment; however, a significant reduction was observed at follow-up (n = 13). C, Total HIV-1 DNA (n = 14) was analyzed with digital droplet polymerase chain reaction from 5 × 106 CD4+ T cells on baseline and follow-up (14 days after last dose). Statistical comparisons were 2-tailed, Wilcoxon signed-rank test as paired analysis against baseline. *P < .05.

Article Snippet: As 120 mg MGN1703 per week is considered safe in cancer patients and healthy controls [ 18 , 21 , 22 ], study participants received 4 weeks of 60 mg (concentration 15 mg/mL) of MGN1703 (MOLOGEN AG, Berlin, Germany), administered subcutaneously by the study investigator as two 2-mL bilateral injections twice weekly.

Techniques: Clinical Proteomics, Virus, Polymerase Chain Reaction